Orthocell Achieves Strongest Month of U.S. Remplir Sales Since Launch
Key points
- October U.S. sales of 92 Remplir units generated AU$279,000 in revenue
- Represents an 84% uplift on average monthly sales of 50 units during Q1 FY27
- Reflects growing surgeon adoption and increased product utilization
Full summary
Orthocell Limited (ASX: OCC) reported the strongest month of U.S. sales for its nerve repair product, Remplir, since its launch. In October 2026, the company sold 92 Remplir units, generating AU$279,000 in revenue, marking an 84% increase from the average monthly sales of 50 units during Q1 FY27. This significant uplift reflects growing surgeon adoption, increased repeat use, a broader base of actively selling distributor representatives, and expanded hospital access across key U.S. markets. The performance demonstrates progress in converting expanded market access into increased product utilization and revenue.
Outlook
The Board remains confident in the product's significant U.S. market potential and the Company's strategy to translate growing market adoption into long-term commercial success.
Summary generated by a large language model. Please interpret with care.